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Defining an olfactory receptor 
function in airway smooth muscle 
cells
William H. Aisenberg1,*, Jessie Huang2,*, Wanqu Zhu2,*, Premraj Rajkumar1,*, Randy Cruz2, 
Lakshmi Santhanam3, Niranjana Natarajan1, Hwan Mee Yong2, Breann De Santiago2, 
Jung Jin Oh2, A-Rum Yoon2, Reynold A. Panettieri4, Oliver Homann5, John K. Sullivan6, 
Stephen B. Liggett7, Jennifer L. Pluznick1 & Steven S. An2,8,9
Pathways that control, or can be exploited to alter, the increase in airway smooth muscle (ASM) mass 
and cellular remodeling that occur in asthma are not well defined. Here we report the expression of 
odorant receptors (ORs) belonging to the superfamily of G-protein coupled receptors (GPCRs), as 
well as the canonical olfaction machinery (Golf and AC3) in the smooth muscle of human bronchi. In 
primary cultures of isolated human ASM, we identified mRNA expression for multiple ORs. Strikingly, 
OR51E2 was the most highly enriched OR transcript mapped to the human olfactome in lung-resident 
cells. In a heterologous expression system, OR51E2 trafficked readily to the cell surface and showed 
ligand selectivity and sensitivity to the short chain fatty acids (SCFAs) acetate and propionate. These 
endogenous metabolic byproducts of the gut microbiota slowed the rate of cytoskeletal remodeling, as 
well as the proliferation of human ASM cells. These cellular responses in vitro were found in ASM from 
non-asthmatics and asthmatics, and were absent in OR51E2-deleted primary human ASM. These results 
demonstrate a novel chemo-mechanical signaling network in the ASM and serve as a proof-of-concept 
that a specific receptor of the gut-lung axis can be targeted to treat airflow obstruction in asthma.
Asthma is a chronic airway inflammatory disease that afflicts over 300 million individuals worldwide1. The major 
cause of morbidity and mortality of the disease is airflow obstruction, which is in part due to actively constricted 
smooth muscle of human bronchi, as well as increased smooth muscle mass2–4. Therapies for airflow obstruction 
from airway smooth muscle (ASM) contraction include the use of antagonists to receptors for specific spasmo-
gens that are released locally due to inflammation or other triggers, or β -agonists, which are direct bronchodi-
lators acting on ASM β 2-adrenergic receptors (β 2ARs)5,6. Both approaches utilize G-protein coupled receptors 
(GPCRs) as targets, and indeed GPCRs are extensively expressed on human ASM7.
We have undertaken studies of this superfamily of receptors8 to identify new targets for treating the contrac-
tion and proliferative phenotypes of ASM in asthma. Unexpectedly, we9 and others10 have found expression of 
multiple bitter taste ‘sensory’ GPCRs (TAS2Rs) in the lung, in particular motile cilia of airway epithelium and 
ASM of human bronchi. In these lung-resident cells, similar to type II taste receptor cells on the tongue11, activa-
tion of TAS2Rs mediates the coupling of the gustducin G protein (Ggust) to phospholipase Cβ (PLCβ ) and evokes 
an increase in intracellular calcium ([Ca2+]i). In motile cilia, this rise in [Ca2+]i enhances ciliary beat frequency 
and, hence, is posited to play a role in mucus clearance10. In ASM, TAS2R-mediated increases in [Ca2+]i, and con-
trary to the classical excitation-contraction mechanisms12, cause membrane hyperpolarization, ASM relaxation, 
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and bronchodilation9. TAS2Rs are broadly tuned, and bitter compounds of diverse structures are effective in 
interdicting the muscle’s mechanical force on the airway via an entirely different cascade of signals compared to 
conventional β -agonists13–15. Certain bacteria are known to secrete substances that act as TAS2R agonists, which 
may be the evolutionary basis for expression of these receptors on cilia and ASM, acting to increase mucous clear-
ance and airway opening, respectively.
In the last decade, a number of the other sensory GPCRs (i.e. visual, taste and odorant receptors) that were 
long thought to be specific to classic sensory physiology have been found on other tissues, where they serve as 
selective and sensitive photo/chemoreceptors16–20. For example, a non-image-forming opsin (Opn4) is found in 
the smooth muscle lining blood vessels, where it promotes light-dependent vasorelaxation20. Olfactory-like che-
mosensory signaling is found in a variety of tissues outside of the main olfactory epithelium19,21,22 and is reported 
to play diverse homeostatic roles. These include sperm chemotaxis23, muscle cell migration24, renin secretion and 
blood pressure control25,26, and ventilation in response to hypoxia27. Although the selective pressures or evolu-
tionary context that have led to these receptors being expressed in non-sensory tissues is not entirely clear, these 
findings have now given rise to the notion that agents acting upon these receptors may represent a previously 
unrecognized sensory system that may provide for novel therapeutic targets. Given that olfactory receptors (ORs) 
are the largest family of GPCRs in the superfamily28, and can detect and discriminate volatile environmental 
chemicals over a wide odorant space29, here we applied molecular-screening, whole-transcriptome and single-cell 
analyses to interrogate the expression landscape of ORs in human ASM cells with the goal of identifying recep-
tors that might promote or modify the asthmatic phenotype. The results of these studies identified a physiologic 
function of OR51E2 that could be exploited further for treatment of obstructive lung disease by decreasing ASM 
remodeling and muscle mass.
Results
Novel olfactory-like chemosensory network in human ASM cells. Olfactory sensory neurons 
(OSNs) in the main olfactory epithelium can detect and discriminate volatile chemicals of a wide odorant space29. 
Each of the hundreds of mammalian ORs expressed in individual OSNs signals through a single common path-
way: the olfactory G protein (Golf) and the olfactory form of adenylyl cyclase III (AC3)30,31. Hence, we initially 
probed for transcript levels of these obligate constituents of the olfactory machinery in isolated human ASM 
cells by RT-PCR. As shown in Fig. 1a, primary human ASM cells in culture expressed both Golf and AC3. These 
RT-PCR products were confirmed by sequencing and found to be indistinguishable from previously published 
sequences from the olfactory epithelium.
In order to detect potential ORs expressed in ASM, we then utilized a PCR approach employing degenerate 
primers capable of amplifying the entire repertoire of ORs, as we and others have documented previously19,32. 
Using this low stringent strategy, followed by sequencing of the PCR products, we identified 4 different ORs 
(OR1J1, OR2A1, OR6A2, and OR51E2) and one OR pseudogene OR2A20P. We confirmed the presence of each 
candidate ASM OR using RT-PCR with gene-specific primers (Fig. 1b and Supplementary Fig. 1). As shown in 
Fig. 1b, mRNA encoding OR1J2 (highly similar to OR1J1) was also found to be present in human ASM. These 
results demonstrate that human ASM cells express multiple ORs and their recognized downstream signaling 
components.
Heterologous expression of human ASM ORs. We next cloned and sequenced all identified ASM ORs, 
and ectopically expressed each of the full-length OR mRNAs in HEK-293T cells (Fig. 1c,d). We conducted these 
cell surface trafficking studies because most ORs are found to be trapped in the endoplasmic reticulum when 
transfected into model cells33, and thus the majority of ORs remains orphan receptors. As shown in Fig. 1d, 
Flag-tagged full-length constructs encoding OR1J1, OR6A2 and OR51E2 were able to traffic to the cell surface 
under certain conditions; surface expression of OR51E2 was the most pronounced among the three ORs. In fact, 
OR51E2 incorporated into the plasma membrane without the aid of an N-terminal leucine-rich cleavable signal 
peptide (Lucy tag, as previously described34), or co-expression of RTP1S and Ric8b chaperones (Fig. 1d). In 
contrast, the surface expression of OR1J1 and OR6A2 required the Lucy tag and co-expression of the chaperone 
proteins (Fig. 1d). However, even with the Lucy tag and the chaperones, OR1J2 and OR2A1 failed to reach the 
plasma membrane (Fig. 1d).
Human body atlas of ASM ORs. In order to validate the expression results, we ascertained the expres-
sion of these de novo identified ASM ORs (OR1J1, OR1J2, OR2A1, OR6A2, and OR51E2) in the lung and other 
human organs. First, we surveyed RNA-Seq data from the Genotype-Tissue Expression Project (GTEx) which 
profiled 30 different tissue types35. In this dataset, transcripts for the ASM ORs (OR1J1 and OR1J2 encoded on 
chromosome 9; OR2A1 encoded on chromosome 7; and OR6A2 and OR51E2 encoded on chromosome 11) 
were noted to be expressed in multiple tissues, albeit at low levels (Fig. 2a), and were also found in a subset of 
immune cells (Supplementary Fig. 2; RNA-Seq immune cell dataset from the BLUEPRINT project). As expected, 
ASM ORs were also reported in whole lung tissue (Fig. 2a). In order to further map these sequence data to other 
structural cell-types of the lung, we then utilized an RNA-Seq lung cell dataset comprising cultured epithelial, 
endothelial, fibroblast and smooth muscle cells (Amgen, Inc., Thousand Oaks, CA). Three of the ASM de novo 
identified ORs (OR51E2 > OR1J2 > OR2A1) were among the most highly enriched OR transcripts in these cell 
types (Supplementary Table 1). The other two ORs (OR6A2 and OR1J1) were detected, but at very low abun-
dance (Supplementary Table 1 and Fig. 2b). Of note, while multiple OR genes/pseudogenes are encoded and 
clustered in close proximity of OR51E2 on chromosome 11, robust expression of only OR51E2 was detected 
across lung-resident cells (Supplementary Fig. 3). Using RT-PCR, we confirmed the expression profile of the most 
abundant lung-resident ORs (Fig. 2b) in human ASM cells isolated from multiple lung donors (Fig. 2c).
www.nature.com/scientificreports/
3Scientific RepoRts | 6:38231 | DOI: 10.1038/srep38231
OR51E2 activation modulates cytoskeletal remodeling in ASM. Ligands for sensory receptors are 
often generated by essential physiological processes, such as fermentation of non-digestible polysaccharides by 
the gut microbiota26,36–39. Toward this end, OR51E2 and its murine ortholog (Olfr78) have been reported to 
respond to metabolic byproducts of anaerobic bacterial fermentation, including short chain fatty acids (SCFAs) 
and lactate26,27. First we ascertained the agonist activation profile of OR51E2 expressed in HEK-293T cells to 
define agonists for use in ASM cells. We used a luciferase-based reporter assay in which OR-ligand binding evokes 
increased intracellular cyclic-AMP (cAMP) that in turn drives a cAMP response element-dependent expression 
of luciferase. As shown in Fig. 3a, while formate and butyrate had no effect, acetate and propionate increased 
luciferase expression in a concentration-dependent manner, consistent with the reported receptor-ligand pairing 
of OR51E2/Olfr78 in the kidney26. Recently, Chang and colleagues27 reported lactate as a ligand for the murine 
ortholog of OR51E2 (Olfr78). Indeed, we found that Olfr78 responded to lactate–albeit with a higher EC50 than 
previously reported (Supplementary Fig. 4a). Lactate failed to activate OR51E2 within the physiological range of 
lactate concentrations, however (Supplementary Fig. 4b). Thus, we undertook mechanistic studies to ascertain the 
cellular function of OR51E2 in isolated ASM cells using the metabolic byproducts of anaerobic bacterial fermen-
tation, acetate and propionate, that evoked the aforementioned second messenger response.
Because OR51E2 signals through Golf and AC3, and because β 2AR relax ASM by generating cAMP15, we first 
probed dynamic changes in ASM stiffness in response to a panel of SCFAs using magnetic twisting cytometry 
(MTC). In this method, we applied forced motions of a functionalized bead tethered to the underlying cytoskel-
eton through the cell surface integrin receptors. Dynamic changes in the stiffness measured with this single-cell 
technology are robust indices for contraction and relaxation of isolated ASM cells4,9. Unlike bitter tastants of 
diverse structures that caused rapid and substantial decreases in the stiffness of isolated human ASM cells9, none 
of the SCFAs in the range typically detected in the digestive tract, serum and/or the lung (0.1–10 mM38,40–42) 
or in the range of detection of cAMP signaling of OR51E2 (EC50 = ~2 mM), caused acute changes in the cell 
stiffness (data not shown), nor did they alter histamine-induced single-cell contraction (Supplementary Fig. 5a). 
Figure 1. Expression of olfactory receptor mRNA transcripts in human ASM and transfected HEK-293T 
cells. (a) Golf and AC3 are both expressed in human ASM cells (sequenced to confirm). (b) The five ORs 
transcripts identified by degenerate PCR were also confirmed in human ASM, using gene-specific primers to 
each OR. Mock RT samples (below) serve as negative controls. (c) Confirmed expression of the full-length 
transcript of OR51E2 in RT, but not in mRT. (d) Three of the five ASM ORs are able to traffic to the surface 
of HEK-293T cells. The top panel shows cell surface OR population as detected by immunostaining against 
an N-terminal extracellular FLAG epitope tag with a polyclonal antibody. For detecting the internal OR 
population, cells were subsequently fixed, permeabilized, and stained again for Flag using a monoclonal 
antibody (bottom panel). All constructs with the exception of OR51E2 contain a leucine rich N-terminal signal 
peptide and are co-transfected with chaperon proteins as previously described26,34; “+ ” and “− ” indicate cell 
surface localization of ORs.
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Consistent with the absence of a rapid relaxation effect, we were unable to detect an increase in intracellular 
cAMP in ASM cells from acetate or propionate exposures of 30 min and 4 h (data not shown) using a sensitive 
immunofluorescence assay which we have previously utilized for isolated ASM43. This was true even when phos-
phodiesterase inhibitors were added to the media (data not shown). We noted, however, appreciable decreases 
in baseline cell stiffness with prolonged (24 h) exposures to acetate and propionate (Supplementary Fig. 5b). This 
delayed response is not typical of a cAMP promoted, PKA dependent, relaxation as is found with β 2AR agonists, 
suggesting another mechanism of action. These results prompted us to explore, in time and space, other mechan-
ical/physiological correlates that might be affected by SCFAs, including the rate of cytoskeletal remodeling and 
cellular proliferation.
As shown in Fig. 3b, 24 h exposures to acetate and propionate, but not formate and butyrate, decreased spon-
taneous nanoscale motions of individual functionalized beads on human ASM cells. We characterized these 
unforced bead motions by computing the mean square displacements (MSDs) of all beads as a function of time t. 
For all conditions, computed MSDs of unforced beads increased with t as a power law with an exponent α greater 
than unity (Fig. 3c,d). As such, these anomalous motions are non-thermal in nature44, and represent a discrete 
molecular-level rearrangement of the underlying cytoskeletal network that is driven by an additional source of 
energy in the living cell45,46, a phenomenon termed cytoskeletal remodeling. Compared with untreated human 
ASM cells, those treated with acetate and propionate, but not formate or butyrate exhibited decreases in the com-
puted MSDs, which are apparent at times > 10 s and up to 300 s (Fig. 3c–f). These decreases in MSDs in response 
to acetate and propionate were dose dependent (Supplementary Fig. 5c,d). There were no statistical differences 
in the super-diffusive exponent α across the groups (Fig. 3d). Interestingly, cells treated with acetate showed an 
appreciable decrease in the diffusion coefficient (D*), which is a measure of the incremental step of spontaneous 
bead motion (Fig. 3e). None of the other SCFAs, including propionate, significantly altered D* as compared to 
that of untreated cells.
OR51E2/Olfr78 is the chemo-mechanical receptor for the SCFAs acetate and propionate 
in ASM. To ascertain if the discrete cytoskeletal remodeling events induced by acetate and propionate are 
mediated via OR51E2 in human ASM cells, we next applied the clustered regularly interspaced short palindro-
mic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) to perform loss-of-function studies. Consistent 
with results shown above (Fig. 3), in mock transfected primary human ASM cells, 24 h exposures to acetate 
Figure 2. Human body atlas of ASM OR. (a) Expression of the five de novo identified ASM ORs across 30 
human tissue types (GTEx RNA-Seq tissues). Each colored block provides a quantile spread representing 
expression levels expressed as fragments per kilobase of transcript per million mapped reads (FPKM) across 
all samples of that tissue type. The color at the middle of the strip represents the median expression, and the 
color at the end of the strip represents the maximum expression. A complete absence of reads over an OR 
is represented as grey. The number of human samples in the collection is displayed next to the tissue name. 
(b) Cultured lung cell expression of the indicated ORs (also see Supplementary Table 1). (c) RT-PCR cross-
validation of the most abundant lung-resident OR genes (shown in panel b) in human ASM cells isolated from 6 
non-asthmatic lung donors. Results are shown as 2−ΔCt X 10000, where Δ Ct = [Ct(target gene) − Ct(gapdh)].
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and propionate decreased cytoskeletal remodeling dynamics (Supplementary Fig. 6). In OR51E2-edited human 
ASM cells, propionate decreased the rate of cytoskeletal remodeling while there was no effect from acetate 
(Supplementary Fig. 6). We were not able to definitively validate the efficiency of RNA-guided endonucleases in 
deleting OR51E2 protein in the primary human ASM, because of the poor sensitivity of the commercially avail-
able antibodies for OR51E2. This difficulty and the lack of a loss of responsiveness to acetate in OR51E2-edited 
human ASM cells prompted us to study the OR51E2 murine ortholog Olfr78. This approach provided for use of a 
highly sensitive and validated Olfr78 antibody and to examine several inbred mouse strains.
As shown in Fig. 4a–c, we designed guide RNAs to target Cas9 to the exon 4 of Olfr78 gene in primary ASM 
cells isolated from three different mouse strains (AJ, BALB/c, and C57BL/6). Under basal conditions, we noted 
differential protein expression levels of Olfr78 in isolated mouse ASM cells: AJ cells exhibited the highest Olfr78 
expression, followed by BALB/c and C57BL/6 (Fig. 4c and Supplementary Fig. 7a). Across the three primary 
mouse ASM cells, however, CRISPR-Cas9 successfully reduced Olfr78 protein expression with robust decreases 
particularly noted in BALB/c and C57BL/b ASM cells. In WT C57BL/6 cells, 24 h exposures to acetate and pro-
pionate decreased the dynamics of cytoskeletal remodeling (Fig. 4d). Compared with untreated cells, the rate of 
cytoskeletal remodeling was significantly reduced in cells treated with acetate and propionate. In Olfr78-edited 
cells, however, the dynamics of cytoskeletal remodeling were unaffected by both acetate and propionate. Taken 
together, these results in isolated human and mouse ASM establish that acetate and propionate are agonists for 
Figure 3. De-orphanization of OR51E2 signaling and function in human ASM. (a) Agonist profiles of 
OR51E2 as detected by a luciferase-based reporter assay in transfected HEK-293T cells. For each ligand dosage/
condition (n = 3), we used ANOVA followed by the Student-Newman-Keuls method to determine significance. 
Data are presented as mean ± SE (*P < 0.05 vs. 0 mM dose considered significant). (b) Trajectories of unforced 
motions of RGD-coated beads functionalized on the living human ASM. Spontaneous bead motions were 
recorded over the course of 5 min (10X Objective). Cells were treated for 24 h with or without 10 mM of the 
respective SCFAs (formate, acetate, propionate, and butyrate). For clarity, only a few representative tracings 
(n = 20) are depicted for each experimental conditions. (c) The trajectories of bead motions in two dimensions 
were characterized by computed mean square displacement (MSD) of all beads as function of time t. Data are 
presented as mean ± SE (untreated, n = 15; formate, n = 9; acetate, n = 15; propionate, n = 17; butyrate, n = 5 
individual cell-wells, comprising ~442-1874 individual beads measurements). (d,e) For each individual cell-
well, the exponent α and the diffusion coefficient (D*) were estimated from a least square fit of a power law. (f) 
MSD measured at 10 s and 300 s, respectively. *P < 0.05 compared with untreated cells by ANOVA and post hoc 
t-tests.
www.nature.com/scientificreports/
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OR51E2/Olfr78 and that such olfactory-like chemosensory signal transduction affects the dynamics of the under-
lying cytoskeletal network in ASM.
It is interesting to note that AJ ASM cells, which intrinsically expressed the highest Olfr78 protein, exhib-
ited the least degree of cytoskeletal remodeling compared to the other strains (Fig. 4a) and showed no further 
decreases in the remodeling in response to acetate and propionate (data not shown). We speculate this may be 
due to spontaneous activation of the unoccupied receptors and, hence, the saturation of signal transduction47,48. 
In support of this notion, overexpression of human OR51E2 in isolated C57BL/6 mouse ASM cells caused appre-
ciable slowing of the cytoskeletal remodeling in the absence of the agonists (Fig. 4e,f and Supplementary Fig. 7b).
Activation of OR51E2 inhibits human ASM proliferation. In addition to the cytoskeletal effects, we 
found that acetate and propionate inhibited cellular proliferation of isolated human ASM cells in culture (Fig. 5). 
Here, propionate appeared to be more effective than acetate, and indeed a 24 h exposure to propionate was suf-
ficient to inhibit DNA synthesis and substantially depress cellular proliferation (Fig. 5a,b). By 6 days in culture, 
both acetate and propionate significantly attenuated ASM proliferation (Fig. 5c). These inhibitory effects of ace-
tate and propionate were absent in OR51E2-edited primary human ASM cells (Fig. 5d). We also noted that human 
ASM expressed GPCRs of the GPR family (GPR41 and GPR43), albeit at substantially lower expression levels 
than OR51E2 (Supplementary Table 1 and Supplementary Fig. 8a). GPR41 and GPR43 exhibit ligand profiles sim-
ilar to that of OR51E226,36–39. As shown in Supplementary Figure 8b–e, however, shRNA-mediated knockdown 
of GPR41 or GPR43 did not attenuate either acetate- or propionate-induced inhibition of ASM proliferation in 
culture. Collectively, these results demonstrate that an additional chemoreceptor effect of OR51E2 expressed in 
ASM for the agonists acetate and propionate is a prolonged inhibition of cellular proliferation.
Figure 4. Characteristics of the OR51E2 homologue Olfr78. (a) Cytoskeletal dynamics of ASM cells derived 
from several inbred mouse strains as measured by SNTM. Data are presented as mean ± SE (AJ, n = 825; 
BALB/c, n = 599; C57BL/6, n = 805 individual beads measurements). (b) A schematic diagram of murine Olfr78 
locus and its exons; three target sites in exon 4 are shown below, indicating the CRISPR N20NGG target sites. 
(c) Genome editing efficiency of CRISPR-Cas9 in the primary mouse ASM cells as determined by western blot. 
Full-length gels/blots are presented in Supplementary Figure 7a. (d) Computed MSD at 300 s for Olfr78 WT and 
Olfr78 KO cells (C57BL/6) in response to 24 h exposures to acetate and propionate (10 mM). Data are presented 
as geometric mean ± 95% CI (n = 307–379 individual beads measurements for each group). (e) Isolated mouse 
ASM cells (C57BL/6) were transfected with or without FLAG-tagged full-length construct encoding human 
OR51E2. OR51E2 protein expression was detected by anti-Flag antibody. Full-length gels/blots are presented in 
Supplementary Figure 7b. Although the expected band is ~36 kDa, ORs typically also appear as multiple higher 
molecular weight bands34. (f) Computed MSD at 300 s for wild-type (WT) and OR51E2-overexpressing (Flag-
OR51E2) mouse ASM cells. Data are presented as geometric mean ± 95% confidence interval (n = 354–364 
individual beads measurements for each group).
www.nature.com/scientificreports/
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OR51E2 mitigates increased ASM mass in asthmatic ASM cells. A cardinal feature of airway 
remodeling in asthma is increased ASM mass2, which is a combination of hypertrophy and hyperplasia. And 
indeed, cultured human ASM cells derived from asthmatics have an increased proliferation rate compared to 
non-asthmatic cells49. Hence, we assessed the effects of acetate and propionate to inhibit the proliferation of 
ASM cells derived from asthmatics in culture. For these studies, we used human ASM cells prepared from six 
independent asthmatic lung donors. As shown in Fig. 5e, we detected a variable level of OR51E2 mRNA between 
ASM lines derived from different individuals. There was no statistical difference in OR51E2 mRNA between asth-
matic and non-asthmatic cells. Importantly, similar to non-asthmatic cells, both acetate and propionate effectively 
inhibited cellular proliferation of asthmatic ASM in culture (Fig. 5f). These findings suggest that OR51E2 is intact 
and operational in ASM from asthmatic lungs, and that its ligands, acetate and propionate, could potentially mit-
igate increased ASM mass associated with asthma pathology.
Discussion
Here we demonstrate expression of odorant receptors in primary human ASM cells. ORs that are expressed on 
human ASM were also found in a variety of human tissues, including other structural cells of the lung. OR51E2 
was expressed in multiple lung-resident cells, including the smooth muscle of human bronchi. Transfected 
OR51E2 trafficked readily to the cell surface of HEK-293T cells and showed dose-dependent responsiveness to 
the SCFAs acetate and propionate, but not butyrate or formate. In ASM, acetate and propionate caused reductions 
in the rate of cytoskeletal remodeling as well as cellular proliferation. These physiologic effects were mediated via 
OR51E2 as indicated by loss of function in gene-edited cells. OR51E2 expression was not altered in ASM cells 
derived from asthmatic subjects compared to non-asthmatic, and activation depressed cellular proliferation of 
the asthmatic ASM cells.
Interestingly, OR51E2 activation did not result in acute ASM relaxation, which might be expected since in 
olfactory epithelium the signal transduction of OR51E2 and other olfactory receptors is linked to cAMP produc-
tion. And indeed, we observed dose dependent increases in cAMP (as assayed by a luciferase reporter) in OR51E2 
transfected HEK-293T cells. However, consistent with the lack of acute relaxation, we were unable to measure an 
Figure 5. Activation of OR51E2 inhibits ASM proliferation. (a) Representative photomicrographs of cells 
treated for 24 h with or without formate, acetate, and propionate (10 mM) as measured by EdU cell proliferation 
assay. EdU positive nuclei are labeled with Alexa Fluor 647 (purple), and all nuclei are labeled with DAPI (blue). 
(b) The ratio of Alexa Fluor 647 positive and DAPI positive nuclei were counted in four non-overlapping fields 
per sample. Data are presented as mean ± SE (n = 3 independent samples). (c) ASM proliferation was measured 
by live cell counting over 6 days in culture with SCFAs. Data are presented as mean ± SE (n = 4 independent 
measurements). (d) The effects of SCFAs on cellular proliferation of WT and OR51E2 KO cells as quantified 
by Cell Counting Kit-8 (CCK-8, Sigma). For these studies, cells were treated for 24 h with 10 mM SCFAs and 
then 1 mM SCFAs for the next 5 days in culture. CCK-8 assay was performed on day 6. Data are presented as 
mean ± SE (n = 3 independent measurements). (e) The relative transcript levels of OR51E2 in isolated human 
ASM (non-asthmatics, n = 6 lung donors; asthmatics, n = 6 lung donors). (f) The effects of SCFAs, acetate and 
propionate, on cellular proliferation of asthmatic ASM derived from 6 independent lung donors as measured by 
live cell counting over 6 days in culture.
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increase in whole-cell cAMP in human ASM. This may be due to compartmentalization of cAMP signaling by 
OR51E2 and thus a negligible increase in total intracellular cAMP. Alternatively, OR51E2 could couple to other 
G-proteins or effectors in ASM leading to the observed physiological effects. Indeed, many GPCRs that were at 
one time thought to couple to one G-protein/pathway have now been shown to couple to other G-proteins, or 
even to non G-protein pathways48. This “multidimensional” signaling can be highly cell-type dependent48, which 
often calls for studying a given receptor in the cell-type of interest, as we have carried out in the current study. 
Indeed, our studies with TAS2Rs in ASM also show a divergence from the classical signaling pathway described 
for this receptor in sensing bitter tastants in taste buds9. In taste cells, TAS2R activation by agonists causes cell 
membrane depolarization due to coupling to a transient receptor potential channel. In contrast, activation of 
ASM TAS2Rs by the same agonists causes membrane hyperpolarization, highlighting the cell-type specific nature 
of GPCR signaling events. In the current study, we are confident that the responses we have observed to known 
OR51E2 agonists in human ASM are in fact due to this receptor being activated because of the loss of physiologic 
function when the OR51E2 gene was deleted. The two functions that we have identified in ASM that result from 
OR51E2 activation are consistent with structural and physiological events that would become most apparent 
with chronic activation of the receptor. Both a decrease in molecular-level cytoskeletal rearrangement activity 
(remodeling), and cell proliferation, would act to suppress the increased ASM mass observed in asthma and thus 
mitigate airway obstruction in the disease.
In primary human ASM cells in culture, acetate and propionate effectively interdicted cellular proliferation. 
Previously, Fu and colleagues50 have reported that SCFAs inhibit the proliferation and migration of a human 
colonic adenocarcinoma cell line. In addition, SCFAs are known to inhibit T lymphocyte proliferation51 and 
modulate immune inflammatory responses38. In the gut mucosa, these suppressive effects of SCFAs on cellular 
proliferation and inflammation are thought to act through GPR41 and/or GPR43. In ASM, however, we found 
low transcript abundance of GPR41/43 and, moreover, shRNA-mediated knockdown of both GPR41 and GPR43 
did not attenuate either acetate- or propionate-induced inhibition of ASM proliferation in culture.
SCFAs are endogenously generated by fermentation of undigested dietary fibers by the resident anaerobic 
bacteria in the gut41. They are essential energy sources for the epithelial lining of the gastrointestinal tract and 
are potent growth stimulators for the gut microbiota, including Bifidobacterium52. Trompette and colleagues53 
have recently reported that dietary fermentable fiber content influence not only the richness and diversity in 
the microbiota of the gut, but also shape the lung microbiota. In mice fed a high-fiber diet, the authors also 
found increased circulating levels of SCFAs and demonstrated, in turn, reduced allergic immune inflammatory 
responses in the lung in animals treated with acetate or propionate. The authors posited, therefore, that these 
metabolic byproducts of gut (and possibly lung microbiota) might influence the observed reduction in allergic 
airway inflammation and airway hyper-reactivity53. Notably, SCFAs produced by the gut microbiota are absorbed 
into the bloodstream of the host and, thereby, they would be readily able to reach smooth muscle lining the 
vasculature, as well as the airways. Here we provide a new, non-immune mechanism in the gut-lung axis, where 
SCFAs directly activate olfactory receptors expressed on ASM to reduce ASM mass. It is also possible that resident 
lung microbiota may directly produce SCFAs in disease and/or health, although to our knowledge this has not 
yet been directly demonstrated. Taken together, these studies support the long-held view of the beneficial effects 
of dietary fibers and their fermentable SCFAs in various metabolic syndromes, including obesity which is a risk 
factor for asthma54.
Our data identifying an olfactory receptor-based signaling network on ASM has implications for elucidating 
the role of SCFAs, and gut or lung microbiota, in modulating the asthma diathesis. In addition, these data point 
to a new receptor target for potential therapeutics for asthma. Based on our current data, such agents would be 
agonists for OR51E2, which could act to inhibit or reverse the increased ASM mass and its effects on airflow 
obstruction observed in the disease.
Methods
Materials. Unless otherwise noted, reagents were obtained from Sigma-Aldrich with the exception of 
DMEM-Ham’s F-12 (1:1) which was purchased from GIBCO (Grand Island, NY). The synthetic arginine-gly-
cine-aspartic acid (RGD) containing peptide was purchased from American Peptide Company (Sunnyvale, CA).
Cell culture. As described elsewhere9, primary human ASM cultures were established from the proximal 
airways (first through third order bronchi) of deceased donor lungs unsuitable for transplantation in accordance 
with of the Institutional Review Boards at the University of Pennsylvania. Mouse ASM cells were prepared from 
the isolated trachealis of AJ, BALB/c and C57BL/6 mice as described55. All mice (male, 8-wk old) were obtained 
from a commercial supplier (Jackson Laboratory, Bar Harbor, ME) and housed in a conventional animal care 
facility at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD). The animal protocols were 
approved by the Institutional Animal Care and Use Committee for the Johns Hopkins University, and complied 
with Federal and State regulations governing the humane care and use of laboratory animals. Both mouse and 
human ASM cells were maintained in serum-free media for 24 h at 37 °C in humidified air containing 5% CO2 
prior to study. These conditions have been optimized for seeding cultured cells on collagen matrix and for assess-
ing their mechanical properties4,9,55.
Live cell micromechanical methods. Using spontaneous and forced motions of RGD-coated ferrimag-
netic microbeads (~4.5 μ m in diameter) anchored to the cytoskeleton through cell surface integrin receptors 
of the adherent living cell, we detected cytoskeletal remodeling dynamics and the cell stiffness in response to 
a panel of SCFAs, respectively. These methods, spontaneous nanoscale tracer motions (SNTM) and magnetic 
twisting cytometry (MTC) are described in detail elsewhere45,46,55,56. For these studies, ASM cells were plated 
at 30,000 cells/cm2 on collagen-coated plastic wells (96-well Removawell, Immulon II, Dynetech). First, using 
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SNTM, we visualized spontaneous nanoscale displacements of an individual functionalized bead (~50–100 beads 
per field-of-view) and recorded its positions at a frequency of 12 frames/s for tmax ~300 s via a CCD camera (Orca 
II-ER, Hamamatsu, Japan) attached to an inverted optical microscope (Leica Microsystems, Bannockburn, IL). 
The trajectories of bead motions in two dimensions were then characterized by computing the mean square 
displacement of all beads as function of time [MSD(t)] (nm2), as previously described45. Herein, we analyzed 
MSD data for times greater than 10 s and up to 300 s. For individual cells and experimental conditions, diffusion 
coefficient D* and the exponent α of the bead motion were also estimated from a least-square fit of a power-law 
to the average of MSD data versus time.
We then applied forced motions of the functionalized beads using MTC4,9,55,56 and measured the stiffness of 
individual ASM cells. In brief, RGD-coated ferrimagnetic beads bound on the surface of the cell were magnetized 
horizontally with a brief 1,000-Gauss pulse and twisted in a vertically aligned homogeneous magnetic field 
(20 Gauss) that was varying sinusoidally in time. This sinusoidal twisting magnetic field caused both a rotation 
and a pivoting displacement of the bead: as the bead moves, the cell develops internal stresses which in turn resist 
bead motions56. Lateral bead displacements in response to the resulting oscillatory torque were detected with an 
accuracy of 5 nm using an intensity-weighted center-of-mass algorithm56. The ratio of specific torque to bead 
displacements was computed and expressed as the cell stiffness in units of Pascal per nm (Pa/nm).
Cell proliferation assays. Cellular proliferation was measured by live cell counting using an automated cell 
counter (Countess Cell Counter, Invitrogen), as well as Cell Counting Kit-8 (CCK-8, Sigma) and the Click-iT 
EdU Alexa Fluor 647 assay kit (Thermo Fisher). For live cell count and CCK-8 assays, ASM cells were seeded 
on 6-well plates and maintained in complete DMEM-Ham’s F-12 medium supplemented with 10% fetal bovine 
serum (FBS). After 24 h, SCFAs were added, and cells were allowed to grow for 6 days in complete media contain-
ing 10% FBS. Live cell count was performed on days 1, 4 and 6 following SCFAs treatments.
For EdU cell proliferation assay, cells were first seeded on fibronectin-coated glass coverslips in complete 
media at 40% confluence and allowed to adhere for 2 h. This was followed by serum starvation for 18 h. Samples 
were then placed in complete media with the indicated treatments (i.e. untreated, formate, acetate, propionate, 
and butyrate) in the presence of 5-ethynyl-2′-deoxyuridine (EdU; 10−5 mol/L) for 24 h. All experiments were 
performed in triplicate. After 24 h, samples were rinsed with sterile PBS, fixed and permeabilized. EdU positive 
nuclei were labeled with Alexa Fluor 647, and all nuclei were labeled with DAPI. Samples were mounted and 
imaged at x10 magnification (Nikon 80i Epifluorescent microscope equipped with a CoolSnap HQ camera): 
four non-overlapping fields were imaged per sample. Data analysis was performed using the NIS Elements BR 
software. The object count function was used to identify Alexa Fluor 647 positive (proliferating cells) and DAPI 
positive (total cells) nuclei. The ratio of Alexa Fluor 647 positive and DAPI positive nuclei was calculated to obtain 
the fraction of proliferating cells.
Detection of ASM ORs. Total RNA was extracted from human ASM cells using the RNeasy Mini Kit 
according to the manufacturer’s protocols (Qiagen). After DNAse treatment (Qiagen), 1 μ g of purified total RNA 
was used to synthesize cDNA by reverse transcription using iScript cDNA Synthesis Kit (BioRad). As a nega-
tive control, mock-reverse transcription samples were prepared by replacing the iScript reverse transcriptase 
enzyme in the reaction mixture with an equal volume of water. PCR was performed using HotStarTaq Master 
Mix (Qiagen) following standard thermocycling conditions. To detect ORs in human ASM, we used degenerate 
human OR primers, PC1 and PC2, as described in ref. 57. These OR were cloned and sequenced. In addition, 
we performed RT-PCR using gene specific primers for each of the identified ORs. The gene specific OR primers 
were designed by using the NCBI Primer Blast PCR primer designer tool. The sequences of the gene specific 
primers are listed in Supplementary Figure 1. Human genomic DNA was used to test the gene specific primers 
and optimize PCR working conditions. We also ran mock RT-PCR reactions in parallel with all RT reactions, and 
sequenced all amplified bands of expected size to confirm identity.
Real time-PCR. For these studies, cDNA was generated using random hexamer primers and SuperScript II 
Reverse Transcriptase (Applied Biosystems), and real-time PCR was performed using TaqMan Universal PCR 
Master Mix, fluorogenic probes, and oligonucleotide primers. Unless otherwise stated, we used 2−ΔΔCt method to 
calculate the relative fold change (RFC) of transcripts normalized to a house-keeping gene (GAPDH).
OR trafficking and surface localization. ORs identified in ASM by degenerate primer PCR were cloned 
into the PME18S mammalian expression vector containing N terminal Lucy, Flag and Rho tags as previously 
described34. These constructs were then transfected into HEK 293T cells with and without the chaperone pro-
teins RTP1S and Ric8b. The ability of each construct to traffic and incorporate into the plasma membrane 
was determined by surface immunofluorescence as previously described34. This consisted of staining live 
non-permeabilized cells with rabbit polyclonal anti-Flag antibody (Sigma) at 4 °C. In order to label the internal 
OR population, cells were then fixed with 4% paraformaldehyde, permeabilized with 0.3% Triton-X 100, and 
stained with a monoclonal anti-Flag antibody (Sigma). Primary antibodies were detected using Alexa Fluor goat 
anti-rabbit 555 (for surface ORs) and goat anti-mouse 488 (for internal ORs) secondary antibodies (Invitrogen).
Luciferase assay. An OR51E2, Olfr78 or pcDNA4 construct was transfected into HEK 293T cells with a 
CREB-dependent luciferase (firefly) and a constitutively active luciferase (renilla). OR51E2 and Olfr78 constructs 
were Lucy-Rho-Flag tagged and co-transfected with RTP1S and Ric8b, as previously described34. When stim-
ulated by a ligand, ORs signal though the cAMP second messenger. The rise in cAMP within the cell drives an 
increase in firefly expression, which can be measured using a FLUOstar Omega microplate reader (BMG labtech). 
Firefly luciferase levels are measured relative to the constitutively active renilla allowing for normalization of the 
assay to transfection efficiency and variation in cell number. Here transfected cells were plated on 96-well tissue 
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culture plates for ~20 h prior to the exposure to chemical ligands for 4 h. After 4 h, cells were lysed, and firefly/
renilla ratios were measured in triplicate, as described previously26,34. For graphs comparing data from more than 
one construct (i.e., Olfr78 vs. pcDNA4), each construct/condition is normalized to its’s own control (0 mM).
CRISPR-Cas9. Two single-guide RNAs (sgRNAs) targeting the human OR51E2 gene (Supplementary Fig. 6a) 
and three sgRNAs targeting the murine Olfr78 gene (Fig. 4a) were designed with the assistance of the CRISPR 
Design Tool from the Zhang laboratory at the Massachusetts Institute of Technology (http://crispr.mit.edu). The 
sgRNA oligos were cloned into lentiCRISPRv2 plasmid (Addgene) as previously described58. Each plasmid con-
taining inserted sgRNA sequence was verified using Sanger sequencing. To make lentivirus, the constructed len-
tiCRISPRv2 plasmids were co-transfected into HEK 293T cells with packaging plasmids pMD2.G and psPAX2 
(Addgene) using calcium phosphate transfection method in P100 dishes. Packaged lentivirus was then trans-
duced into ASM cells using T25 flask or 6-well plate, followed by puromycin selection for 2–3 days. The surviving 
cells were maintained for another 3 days before isolation of the genomic DNA or proteins.
Sanger sequencing. To determine the genotype and the genome editing efficiency of human OR51E2, PCR 
products amplified from cell population by genomic DNA spanning the CRISPR RNA (crRNA) target site were 
cloned into T vector pMD20 (Takara Bio Inc., Japan). Sanger sequencing was performed on 33 single bacterial 
colonies (Supplementary Fig. 6b). All showed specific ‘indel’ mutations. Thirty one (94%) were of the deletion 
type showing mostly frameshift mutations near the gRNA cut site. Two (6%) were of the insertion type with one 
showing a frameshift mutation. For the genome editing efficiency of mouse Olfr78, we ran western blots using a 
validated antibody for Olfr7859.
Western blotting. ASM cells in culture were first washed with PBS, lysed with SDS Protein-Gel Loading 
Solution (Quality Biological, Inc.), and applied on SDS-PAGE. The separated proteins were then transferred to 
nitrocellulose membranes. Membranes were blocked with 5% nonfat dry milk in Tris Buffered Saline with 0.1% 
Tween, and incubated with the primary antibody followed by HRP-conjugated secondary antibody. HRP-labelled 
bands were detected using an enhanced chemiluminescence (ECL) kit (Pierce) according to manufacturer’s rec-
ommendations. Full-length gels and blots are presented in Supplementary Figure 7.
Amgen lung cell dataset. Primary human bronchial epithelial cells, bronchial smooth muscle cells, lung 
fibroblasts and microvascular endothelial cells from normal or diseased patients were obtained from Lonza 
(Basel, Switzerland). Low passage cells (passage number 4–6) were used for RNA-Seq, and cells were grown to 
~80% confluency before RNA isolation. Bronchial epithelial cells from 3 normal, 3 COPD and 3 asthma donors 
were grown submerged in BEBM Base Media with BEGM Bullet Kit (Lonza). Primary human bronchial smooth 
muscle cells from 3 normal, 3 COPD and 3 asthma donors were cultured in SmBM Base Media supplemented 
with SmGMTM-2 Bullet Kit (Lonza). Lung fibroblasts from 3 normal, 4 COPD and 4 asthma donors were cultured 
in FBM Base Media supplemented with FGM-2 Bullet Kit (Lonza). Lung fibroblasts from seven idiopathic lung 
fibrosis (IPF) patients were obtained from ATCC or Asterand. IPF cells LL29 (AnHa) (ATCC® CCL-134™ ) and 
LL97A (AlMy) (ATCC® CCL-191™ ) were grown in Hanks F12 Media with 15% FBS were and used at passage 5 
and 10, respectively, for RNA-Seq.
RNA-Sequencing. The Amgen cDNA libraries were prepared from total RNA isolated using Mirvana 
miRNA isolation kits (Ambion, Grand Island, NY) with on-colum DNase treatment as described previously60. 
Total RNA quality and concentration was determined using Bioanalzyer (Agilent, Santa Clara, CA) and 
NanoDrop (ThermoScientific, Wilmington, DE) instruments. cDNA was prepared using a modified protocol 
based on the Illumina TruSeq RNA Sample Preparation Kit (Illumina, San Diego, CA) and published meth-
ods for strand-specific RNA-Seq61,62. After size-selection of libraries (Pippen Prep; SAGE Biosciences, Beverly, 
MA), dUTP-containing cDNA strands were eliminated by digestion with USER enzymes (New England BioLabs, 
Ipswich, MA) followed by PCR enrichment for introduction of strand specificity. The enriched cDNA libraries 
were analyzed in Agilent Bioanalzyer and quantified by Quant-iTTM Pico-Green assays (Life Technologies). The 
samples were sequenced on the Illumina HiSeq platform (Expression Analysis Inc, Morrisville, NC) using 75 bp 
paired-end sequencing to a depth of 35–55 million reads.
RNA-Seq data analysis. The gene model used for the study is the Array Studio (OmiSoft, NC) 
“OmicsoftGene20130723” gene model, which was derived from the UCSC database (downloaded on July 23, 
2013; see also http://www.arrayserver.com/wiki/index.php?title= Omicsoft_Gene_Model). OR genes were iden-
tified using the Huge Gene Nomenclature Committee (HGNC) Olfactory Receptor gene set, downloaded on 
September 14th, 2015 (pseudogenes were excluded; we also individually examined any gene in the gene model 
with an “OR” prefix). The gene model contained 375 such ORs. As the primary focus of this investigation was 
OR expression in smooth muscle, we focused on identifying ORs with clear expression in the cultured smooth 
muscle cell samples from the Amgen lung dataset (see Supplementary Methods). ORs were ranked in order of 
descending FPKM, and also considered in the context of cross-sample support, as measured by the number of 
samples with more than one read aligning to the OR. We would like to emphasize that we consider evaluation of 
OR expression using these datasets to be exploratory, as OR expression is generally low and sensitive to technical 
considerations such as library depth and complexity and the noise inherent to quantification of low-abundance 
transcripts. Alignment coverage profiles of the highest ranking ORs (shown in Supplementary Table 1) were 
individually scrutinized in the Array Studio genome browser to ensure that no obvious anomalies were observed 
(e.g. pile-ups of non-unique fragments or coverage that was inconsistent with the gene model). As an example, 
we provide a zoomed out view of OR51E2 RNA-Seq coverage in Supplemental Figure 3, highlighting the robust 
coverage and high specificity of expression in the region. Please see Supplementary Methods for details on other 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:38231 | DOI: 10.1038/srep38231
RNA-Seq datasets employed (i.e. Genotype-Tissue Expression Project; BLUEPRINT Hematopoietic Epigenome 
Project) and the detailed analysis workflow.
Statistical analysis. Unless otherwise stated, data are presented as mean ± standard error of the mean. We 
used unpaired Student’s t-tests, and the analysis of variance (ANOVA) with adjusting for multiple comparisons 
by applying the Bonferroni method. Where indicated, we also applied Student-Newman-Keuls method. To satisfy 
the distributional assumptions associated with t-tests and the ANOVA, stiffness and MSD data were converted 
to log scale prior to analyses. All analyses were performed using SigmaPlot (Systat Software) or GraphPad Prism 
(La Jolla, CA), and 2-sided P values less than 0.05 were considered significant.
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